SubsidieMeestersCell-instructive matrices to deconstruct tumour tissues
The project aims to develop a controllable platform for patient-specific pancreatic cancer models to discover improved therapies targeting tumor biology and cell interactions.
Projectdetails
Introduction
This research addresses a clinical problem with an innovative approach. Pancreatic cancer is one of the deadliest cancers, and only 10% of patients survive 5 years after diagnosis.
Need for Patient-Specific Models
To find better therapies, we need patient-specific models that mimic the biology of tumour tissues and target interactions between different cell types.
Development of a Controllable Platform
We will develop a controllable platform for modelling the human disease in the laboratory.
Goals of the Research
We will use our new platform to discover better ways of treating the disease.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-1-2024 |
| Einddatum | 30-6-2025 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- LEIBNIZ-INSTITUT FUR POLYMERFORSCHUNG DRESDEN EVpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Generation and validation of a panel of EMT reporter cell lines from solid tumorsDevelop a validated toolkit of genetically modified cell lines and culture media to improve drug discovery by accurately representing solid tumor subtypes and their responses to treatment. | ERC Proof of... | € 150.000 | 2022 | Details |
Targeted Re-engineering of the Tumor Matrix to Advance ImmunotherapyThis project aims to disrupt the pro-fibrotic loop in pancreatic cancer using engineered biomimetics to enhance immune therapy efficacy by normalizing the tumor microenvironment. | ERC Advanced... | € 2.499.783 | 2024 | Details |
Development of a high-throughput microplate based device to analyse the patient derived tumour microenvironment3DTUMOUR aims to enhance drug development success by providing patient-specific 3D bioprinted tumour models for ex vivo testing, improving treatment efficacy and reducing toxicity in cancer therapy. | ERC Proof of... | € 150.000 | 2024 | Details |
Personalised Mechanobiological Models to Predict Tumour Growth and Anti-Cancer Drug PenetrationThis project aims to develop a personalized cancer treatment framework by modeling stress-dependent tumor growth and drug penetration to enhance patient-specific therapy outcomes. | ERC Starting... | € 1.499.693 | 2024 | Details |
Proteomic Analysis of Cell communication in TumorsThis project aims to analyze cancer proteome dynamics at single-cell resolution to understand tumor heterogeneity and improve personalized treatment for resistant metastatic cells. | ERC Consolid... | € 2.000.000 | 2022 | Details |
Generation and validation of a panel of EMT reporter cell lines from solid tumors
Develop a validated toolkit of genetically modified cell lines and culture media to improve drug discovery by accurately representing solid tumor subtypes and their responses to treatment.
Targeted Re-engineering of the Tumor Matrix to Advance Immunotherapy
This project aims to disrupt the pro-fibrotic loop in pancreatic cancer using engineered biomimetics to enhance immune therapy efficacy by normalizing the tumor microenvironment.
Development of a high-throughput microplate based device to analyse the patient derived tumour microenvironment
3DTUMOUR aims to enhance drug development success by providing patient-specific 3D bioprinted tumour models for ex vivo testing, improving treatment efficacy and reducing toxicity in cancer therapy.
Personalised Mechanobiological Models to Predict Tumour Growth and Anti-Cancer Drug Penetration
This project aims to develop a personalized cancer treatment framework by modeling stress-dependent tumor growth and drug penetration to enhance patient-specific therapy outcomes.
Proteomic Analysis of Cell communication in Tumors
This project aims to analyze cancer proteome dynamics at single-cell resolution to understand tumor heterogeneity and improve personalized treatment for resistant metastatic cells.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
PRO CellecTPan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren. | Mkb-innovati... | € 20.000 | 2021 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
A multiplexed biomimetic imaging platform for assessing single cell plasticity (Plastomics) and scoring of tumour malignancyThe PLAST_CELL project aims to develop a microfluidics-based imaging platform to quantify cancer cell plasticity, enhancing diagnosis and treatment of metastasis and therapy resistance. | EIC Pathfinder | € 2.982.792 | 2022 | Details |
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkankerDe ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren. | Mkb-innovati... | € 20.000 | 2020 | Details |
AI-based medical assistant - Herkennen en classificeren van tumoren m.b.v. kunstmatige intelligentieDit project ontwikkelt een geavanceerde beeldherkenningstechnologie voor realtime screening van eiwittypologieën in biopten, om de behandeling van complexe tumoren te verbeteren. | Mkb-innovati... | € 200.000 | 2018 | Details |
PRO CellecT
Pan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren.
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.
A multiplexed biomimetic imaging platform for assessing single cell plasticity (Plastomics) and scoring of tumour malignancy
The PLAST_CELL project aims to develop a microfluidics-based imaging platform to quantify cancer cell plasticity, enhancing diagnosis and treatment of metastasis and therapy resistance.
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker
De ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren.
AI-based medical assistant - Herkennen en classificeren van tumoren m.b.v. kunstmatige intelligentie
Dit project ontwikkelt een geavanceerde beeldherkenningstechnologie voor realtime screening van eiwittypologieën in biopten, om de behandeling van complexe tumoren te verbeteren.